Additionally, the 36-month beta value for CERE is 1.44. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 0 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
The average price predicted by analysts for CERE is $34.13, which is $11.79 above the current price. The public float for CERE is 59.54M and currently, short sellers hold a 9.14% ratio of that float. The average trading volume of CERE on September 15, 2023 was 642.22K shares.
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free
CERE) stock’s latest price update
The stock price of Cerevel Therapeutics Holdings Inc. (NASDAQ: CERE) has dropped by -1.19 compared to previous close of 22.60. Despite this, the company has seen a fall of -7.07% in its stock price over the last five trading days. GlobeNewsWire reported 2023-08-29 that CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) — Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, 2023. President and chief executive officer Ron Renaud will participate in a fireside chat at 9:30 AM ET.
CERE’s Market Performance
CERE’s stock has fallen by -7.07% in the past week, with a monthly rise of 2.62% and a quarterly drop of -34.65%. The volatility ratio for the week is 2.91% while the volatility levels for the last 30 days are 3.21% for Cerevel Therapeutics Holdings Inc. The simple moving average for the past 20 days is -2.86% for CERE’s stock, with a -22.49% simple moving average for the past 200 days.
Analysts’ Opinion of CERE
Many brokerage firms have already submitted their reports for CERE stocks, with BofA Securities repeating the rating for CERE by listing it as a “Neutral.” The predicted price for CERE in the upcoming period, according to BofA Securities is $31 based on the research report published on August 03, 2023 of the current year 2023.
CERE Trading at -13.40% from the 50-Day Moving Average
After a stumble in the market that brought CERE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.94% of loss for the given period.
Volatility was left at 3.21%, however, over the last 30 days, the volatility rate increased by 2.91%, as shares surge +4.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.02% lower at present.
During the last 5 trading sessions, CERE fell by -7.07%, which changed the moving average for the period of 200-days by -21.68% in comparison to the 20-day moving average, which settled at $23.03. In addition, Cerevel Therapeutics Holdings Inc. saw -29.20% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CERE starting from COLES N ANTHONY, who sale 50,000 shares at the price of $24.07 back on Sep 07. After this action, COLES N ANTHONY now owns 2,704 shares of Cerevel Therapeutics Holdings Inc., valued at $1,203,415 using the latest closing price.
Burgess Paul D., the of Cerevel Therapeutics Holdings Inc., purchase 21,880 shares at $22.93 during a trade that took place back on Aug 04, which means that Burgess Paul D. is holding 21,880 shares at $501,794 based on the most recent closing price.
Stock Fundamentals for CERE
The total capital return value is set at -46.07, while invested capital returns managed to touch -44.17. Equity return is now at value -83.20, with -40.30 for asset returns.
Based on Cerevel Therapeutics Holdings Inc. (CERE), the company’s capital structure generated 81.90 points at debt to equity in total, while total debt to capital is 45.03. Total debt to assets is 41.94, with long-term debt to equity ratio resting at 81.35. Finally, the long-term debt to capital ratio is 44.72.
The liquidity ratio also appears to be rather interesting for investors as it stands at 12.48.
Conclusion
In conclusion, Cerevel Therapeutics Holdings Inc. (CERE) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
